In vitro co-stimulation of anti-tumor activity by soluble B7 molecules.
In order to investigate the anti-tumor activity of a soluble B7-1/immunoglobulin G fusion protein and explore an effective method to eliminate immune escape of tumor cells, a recombinant vector encoding this fusion protein was constructed and constitutively expressed in Chinese hamster ovary cells. After purification with protein G affinity chromatography, the soluble fusion protein was tested for bioactivity. Results showed that the fusion protein could significantly increase the density of B7-1 molecules on WEHI-3 cells, a mouse leukemia cell line. Through allogeneic mixed lymphocyte tumor cultures, it was demonstrated that, with the presence of the first signal, it could also significantly enhance T cell activation and killing activity against WEHI-3 cells and interleukin-2 secretion by activated mouse T lymphocytes. The conclusion can be drawn that the soluble B7-IgG fusion protein has a potent capacity to generate or enhance anti-tumor immune response in vitro, and its clinical value deserves further investigation.
He
Wei
W
Institute of Haematology, the Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Hu
Zhong-Bo
ZB
Liu
Fang
F
Feng
Xian-Qi
XQ
Zou
Ping
P
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D018122:B7-1 Antigen / Q000235:genetics / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D003602:Cytotoxicity, Immunologic; D007074:Immunoglobulin G / Q000235:genetics / Q000627:therapeutic use*; D007938:Leukemia / Q000473:pathology; D008213:Lymphocyte Activation; D007959:Lymphocyte Culture Test, Mixed; D051379:Mice; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D012995:Solubility
D000970:Antineoplastic Agents; D018122:B7-1 Antigen; D007074:Immunoglobulin G; D011993:Recombinant Fusion Proteins